Within weeks prior to registration: Serum calcium (absolute or albumin corrected), magnesium and potassium >= lower limit of normal (LLN)\r\n* NOTE: serum calcium, magnesium and potassium can be replaced if values are below LLN Uncontrolled hypomagnesemia, hypokalemia or hypocalcemia, defined as values below the lower limit of normal (LLN) for the institution despite adequate electrolyte supplementation or management Serum phosphorus, calcium, magnesium and potassium >= lower limit of normal (LLN) Potassium >= lower limit of normal (LLN) range for the institution Sodium >= LLN Phosphorus >= LLN; NOTE: Supplementation may be given before the first dose of study medication Serum phosphorus, calcium, magnesium and potassium >= lower limit of normal (LLN), within days before the first dose of cabozantinib Serum phosphorus >= lower limit of normal (LLN) within days before the first dose of cabozantinib Potassium >= LLN within days before the first dose of cabozantinib Serum phosphorus >= lower limit of normal (LLN) Potassium >= LLN Serum potassium and magnesium greater than the institutional lower limit of normal (LLN). Serum potassium >= LLN Serum sodium >= LLN Within days before the first dose of study treatment: Serum phosphorus, calcium, magnesium and potassium >= lower limit of normal (LLN) Serum potassium >= lower limit of normal (LLN) Serum sodium >= LLN Serum B and folate levels >= lower limit of normal (LLN) for the laboratory\r\n* Note: Patients may begin B and folic acid supplementation and be reconsidered for participation in the study when levels are >= LLN for the laboratory Serum phosphorus >= lower limit of normal (LLN) Serum potassium >= LLN Fibrinogen >. LLN Within days prior to the first dose of cabozantinib: Serum phosphorus, calcium, potassium >= lower limit of normal (LLN) Serum phosphorus >= lower limit of normal (LLN) Serum potassium >= LLN Phosphorus < LLN Potassium < LLN Serum potassium >= lower limit of normal (LLN) Serum sodium >= LLN RENAL COHORT: Laboratory values as follows within days before the first dose of daratumumab: serum phosphorus ? lower limit of normal (LLN) Within days before the first dose of cabozantinib: Serum phosphorus, calcium, magnesium and potassium >= lower limit of normal (LLN) Potassium >= lower limit of normal (LLN) range for the institution =< days prior to registration\r\n* NOTE: Supplementation may be given before the first dose of study medication Phosphorus >= LLN =< days prior to registration\r\n* NOTE: Supplementation may be given before the first dose of study medication LVEF below institutional LLN or below %, whichever is lower Serum phosphorus, calcium, magnesium and potassium >= lower limit of normal (LLN) Serum potassium >= lower limit of normal (LLN) and serum magnesium >= LLN (electrolyte levels may be achieved with repletion or other supportive medications like potassium sparing diuretics) Subjects with hypokalemia and hypomagnesemia at Screening (defined as values below lower limit of normal [LLN]). Fibrinogen ?. LLN Serum phosphorus >= lower limit of normal (LLN) Potassium >= LLN K+ or Mg+ < LLN. Potassium, magnesium, phosphorus and total calcium values ? LLN (lower limit of normal) Serum potassium ? Institutional lower limit of normal (LLN) Serum phosphorus, calcium and potassium >= lower limit of normal (LLN) Subject has hypokalemia and hypomagnesemia at Screening (defined as values below institutional lower limit of normal [LLN]). Serum potassium >= lower limit of normal (LLN) Serum phosphorus >= LLN Serum phosphorus >= lower limit of normal (LLN) Potassium >= LLN Serum phosphorus >= lower limits of normal (LLN) Serum phosphorus >= lower limit of normal (LLN) Serum potassium >= lower limit of normal (LLN) Serum potassium, magnesium and phosphorus >= lower limit of normal (LLN) and =< . x ULN Sodium >= lower limit of normal (LLN) after correction of hyperglycemia Serum phosphorus, magnesium, calcium and potassium >= lower limit of normal (LLN) Patient must have the following laboratory values or have the following laboratory values corrected with supplements to be within normal limits at screening:\r\n* Potassium >= lower limit of normal (LLN)\r\n* Magnesium >= LLN\r\n* Phosphorus >= LLN\r\n* Total calcium (corrected for serum albumin) >= LLN Serum phosphorus >= lower limit of normal (LLN) (if below LLN, for asymptomatic patients replacement may be initiated if clinically indicated without delaying the start of study treatment) Serum calcium >= LLN (if below LLN, for asymptomatic patients replacement may be initiated if clinically indicated without delaying the start of study treatment) Serum magnesium >= LLN (if below LLN, for asymptomatic patients replacement may be initiated if clinically indicated without delaying the start of study treatment) Serum potassium >= LLN (if below LLN, for asymptomatic patients replacement may be initiated if clinically indicated without delaying the start of study treatment) Serum potassium >= lower limit of normal (LLN) Serum phosphorus >= LLN Serum potassium >= lower limit of normal (LLN) Serum phosphorus >= LLN Serum phosphorus calcium, magnesium and potassium >= lower limit of normal (LLN) Serum phosphorus, magnesium, and potassium >= lower limit of normal (LLN) after adequate supplementation if necessary Serum potassium >= lower limit of normal (LLN) Serum phosphorous >= LLN Serum potassium greater than the lower limit of normal (LLN) and < . mmol/L Serum sodium, potassium, magnesium, phosphate, and calcium > lower limit of normal (LLN) Serum potassium and serum magnesium ? institutional lower limit of normal (LLN).